-
Pandya blitz powers India to T20 series win over South Africa
-
Misinformation complicated Brown University shooting probe: police
-
IMF approves $206 mn aid to Sri Lanka after Cyclone Ditwah
-
US halts green card lottery after MIT professor, Brown University killings
-
Stocks advance as markets cheer weak inflation
-
Emery says rising expectations driving red-hot Villa
-
Three killed in Taipei metro attacks, suspect dead
-
Seven Colombian soldiers killed in guerrilla attack: army
-
Amorim takes aim at Man Utd youth stars over 'entitlement'
-
Mercosur meets in Brazil, EU eyes January 12 trade deal
-
US Fed official says no urgency to cut rates, flags distorted data
-
Rome to charge visitors for access to Trevi Fountain
-
Spurs 'not a quick fix' for under-fire Frank
-
Poland president accuses Ukraine of not appreciating war support
-
Stocks advance with focus on central banks, tech
-
Amorim unfazed by 'Free Mainoo' T-shirt ahead of Villa clash
-
PSG penalty hero Safonov ended Intercontinental win with broken hand
-
French court rejects Shein suspension
-
'It's so much fun,' says Vonn as she milks her comeback
-
Moscow intent on pressing on in Ukraine: Putin
-
UN declares famine over in Gaza, says 'situation remains critical'
-
Guardiola 'excited' by Man City future, not pondering exit
-
Zabystran upsets Odermatt to claim first World Cup win in Val Gardena super-G
-
Czechs name veteran coach Koubek for World Cup play-offs
-
PSG penalty hero Safonov out until next year with broken hand
-
Putin says ball in court of Russia's opponents in Ukraine talks
-
Czech Zabystran upsets Odermatt to claim Val Gardena super-G
-
NGOs fear 'catastrophic impact' of new Israel registration rules
-
US suspends green card lottery after MIT professor, Brown University killings
-
Stocks mixed with focus on central banks, tech
-
Arsenal in the 'right place' as Arteta marks six years at club
-
Sudan's El-Fasher under the RSF, destroyed and 'full of bodies'
-
From farms to court, climate-hit communities take on big polluters
-
Liverpool have 'moved on' from Salah furore, says upbeat Slot
-
Norway crown princess likely to undergo lung transplant
-
Iraq negotiates new coalition under US pressure
-
France's budget hits snag in setback for embattled PM
-
Putin hails Ukraine gains, threatens more, in annual press conference
-
US suspends green card lottery after Brown, MIT professor shootings
-
Chelsea's Maresca says Man City link '100 percent' speculation
-
Dominant Head moves into Bradman territory with fourth Adelaide ton
-
Arsenal battle to stay top of Christmas charts
-
Mexican low-cost airlines Volaris and Viva agree to merger
-
Border casinos caught in Thailand-Cambodia crossfire
-
Australia's Head slams unbeaten 142 to crush England's Ashes hopes
-
Epstein files due as US confronts long-delayed reckoning
-
'Not our enemy': Rush to rearm sparks backlash in east Germany
-
West Indies 110-0, trail by 465, after Conway's epic 227 for New Zealand
-
Arsonists target Bangladesh newspapers after student leader's death
-
Volatile Oracle shares a proxy for Wall Street's AI jitters
Moderna sues Pfizer, BioNTech over Covid vaccine
Moderna said Friday it is suing rival vaccine makers Pfizer and BioNTech, alleging the partners infringed on its patents in developing their Covid-19 shot administered to hundreds of millions around the world.
The lawsuits set up a high-stakes showdown between the leading manufacturers of Covid-19 shots that are a key tool in the fight against the disease.
"Moderna believes that Pfizer and BioNTech's Covid-19 vaccine Comirnaty infringes patents Moderna filed between 2010 and 2016 covering Moderna's foundational mRNA technology," the US-based biotech firm said in a statement.
"Pfizer and BioNTech copied this technology, without Moderna's permission, to make Comirnaty," Moderna alleged.
Pfizer and BioNTech said they were aware of the litigation, and each issued statements denying any wrongdoing.
"BioNTech's work is original, and we will vigorously defend against all allegations of patent infringement," the firm said, adding it "respects valid and enforceable intellectual property rights of others."
Pfizer pledged to "vigorously defend against the allegations of the lawsuit."
The mRNA technology used in the Moderna and Pfizer-BioNTech shots differs from that in traditional vaccines, which rely on injecting weakened or dead forms of a virus to allow the immune system to recognize it and build antibodies.
Instead, mRNA vaccines deliver instructions to cells to build a harmless piece of the spike protein found on the surface of the virus that causes Covid-19.
After creating this spike protein, cells can recognize and fight the real virus, hailed as a major advancement in development of vaccines.
- Key tool against deadly pandemic -
The shots have repeatedly been the subject of inaccurate claims that they are dangerous, but health authorities say they are safe and effective.
The lawsuits -- in US district court in Massachusetts, and in regional court in Dusseldorf, Germany -- are not seeking the removal of the rival vaccine or an injunction on future sales.
Moderna said it had begun building up the technology in 2010 and patented work on corona viruses in 2015 and 2016, which allowed for rollout of its shots in "record time" after the pandemic struck.
The virus has killed at least 6.48 million people worldwide since 2020 and made nearly 600 million ill, according to a Johns Hopkins University tracker.
In addition to death and suffering, the disease has led to a re-shaping of life ranging from a change in norms on working from home to a scrambling of supply chains and workforces.
Moderna said it pledged in October 2020 not to enforce its Covid-19-related patents while the pandemic continued, but less than two years later changed that stance as the fight shifted gears.
"Moderna expected companies such as Pfizer and BioNTech to respect its intellectual property rights and would consider a commercially reasonable license should they request one for other markets," it said.
"Pfizer and BioNTech have failed to do so," the firm added.
These types of lawsuits are not unheard of in the pharmaceutical industry, where patents can be worth billions of dollars, and can take years to resolve.
"It is an unfortunate but rather regular occurrence that other companies make allegations that a successful product potentially infringes their intellectual property rights," BioNTech said in a statement.
O.Lorenz--BTB